• Price (USD)200.16
  • Today's Change-9.23 / -4.41%
  • Shares traded1.68m
  • 1 Year change+3.88%
  • Beta0.5603
Data delayed at least 15 minutes, as of Sep 30 2022 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Key statistics

On Friday, Alnylam Pharmaceuticals Inc (ALNY:NSQ) closed at 200.16, -15.47% below its 52-week high of 236.80, set on Aug 12, 2022.
52-week range
117.58May 12 2022236.80Aug 12 2022
Markit short selling activity
Previous close209.39
Average volume905.36k
Shares outstanding120.03m
Free float119.21m
P/E (TTM)--
Market cap23.69bn USD
EPS (TTM)-8.17
Data delayed at least 15 minutes, as of Sep 30 2022 21:00 BST.
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.